Dose-escalated salvage radiotherapy after radical prostatectomy in high risk prostate cancer patients without hormone therapy: Outcome, prognostic factors and late toxicity

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Shelan, Mohamed ^a   Abo Madyan, Yasser ^a,b   Welzel, Grit ^a   Bolenz, Christian ^a   Kosakowski, Julia ^a   Behnam, Nadim ^a   Wenz, Frederik ^a   Lohr, Frank ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Dose escalation; Radical prostatectomy; Salvage radiotherapy

Indexed keywords

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER SURVIVAL; CLINICAL RELAPSE FREE SURVIVAL; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION DOSE ESCALATION; RADIOTHERAPY; RECURRENCE FREE SURVIVAL; SALVAGE RADIOTHERAPY; SALVAGE THERAPY; TREATMENT OUTCOME;

AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84888216854     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-276     Document Type: Article

References (21)

1. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 2002, 167:117-122. 10.1016/S0022-5347(05)65394-3, 11743287.
2. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989, 141:873-879.
3. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009, 181:956-962. 10.1016/j.juro.2008.11.032, 3510761, 19167731.
4. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, Souchon R, Stockle M, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930. 10.1200/JCO.2008.18.9563, 19433689.
5. Resnick MJ, Cookson MS. Positive surgical margins at radical prostatectomy: much ado about nothing?. Urol Oncol 2013, 31:285-287. 10.1016/j.urolonc.2011.12.005, 23627001.
6. Tomita N, Kodaira T, Furutani K, Tachibana H, Nakahara R, Mizoguchi N, Hayashi N. Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy. J Cancer Res Clin Oncol 2009, 135:1561-1567. 10.1007/s00432-009-0603-7, 19479278.
7. Bottke D, Bartkowiak D, Schrader M, Wiegel T. Radiotherapy after radical prostatectomy: immediate or early delayed?. Strahlenther Onkol 2012, 188:1096-1101. 10.1007/s00066-012-0234-9, 23128897.
8. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007, 25:2035-2041. 10.1200/JCO.2006.08.9607, 2670394, 17513807.
9. Chawla AK, Thakral HK, Zietman AL, Shipley WU. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. Urology 2002, 59:726-731. 10.1016/S0090-4295(02)01540-6, 11992848.
10. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004, 291:1325-1332. 10.1001/jama.291.11.1325, 15026399.
11. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008, 299:2760-2769. 10.1001/jama.299.23.2760, 3076799, 18560003.
12. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002, 167:528-534. 10.1016/S0022-5347(01)69079-7, 11792912.
13. Siegmann A, Bottke D, Faehndrich J, Lohm G, Miller K, Bartkowiak D, Wiegel T, Hinkelbein W. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. Strahlenther Onkol 2011, 187:467-472. 10.1007/s00066-011-2229-3, 21786112.
14. Bernard JR, Buskirk SJ, Heckman MG, Diehl NN, Ko SJ, Macdonald OK, Schild SE, Pisansky TM. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys 2010, 76:735-740. 10.1016/j.ijrobp.2009.02.049, 19464818.
15. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008, 71:23-27. 10.1016/j.ijrobp.2007.09.047, 18207668.
16. Neuhof D, Hentschel T, Bischof M, Sroka-Perez G, Hohenfellner M, Debus J. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys 2007, 67:1411-1417. 10.1016/j.ijrobp.2006.11.024, 17275204.
17. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003, 61:365-369. 10.1016/S0090-4295(02)02268-9, 12597949.
18. Ghadjar P. Letter to the Editor on: A. Siegmann et al. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival. Results of a retrospective study. In: Strahlenther Onkol 2011;187:467-72 (No. 8) (DOI 10.1007/s00066-011-2229-3). P. Ghadjar, D. Zwahlen, D.M. Aebersold: Selection bias is not a good reason for dose intensification in patients with PSA recurrence after radical prostatectomy. Strahlenther Onkol 2011, 187:763. author reply 764, 10.1007/s00066-011-9229-1, 22037657.
19. Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer 2012, 48:837-844. 10.1016/j.ejca.2011.08.013, 21945099.
20. King CR, Presti JC, Gill H, Brooks J, Hancock SL. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?. Int J Radiat Oncol Biol Phys 2004, 59:341-347. 10.1016/j.ijrobp.2003.10.015, 15145146.
21. Shipley WU, Hunt D, Lukka HR, Major P, Heney NM, Grignon D, Patel M, Bahary J, Lawton CA, Sandler HM. Initial report of RTOG 9601, a phase III trial in prostate cancer: effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels. ASCO Meeting Abstracts 2011, 29:1.